WG 3
CLINICAL APPLICATIONS

Leader: Francisco J. Nicolás-Villaescusa (Spain)

Vice Leader: Florelle Gindraux (France)

Aims:

1) To foster networking between researchers and clinicians, from both academia and industry, who perform clinical trials using perinatal derivatives (PnD) for:

a) current tissue engineering and paracrine strategies and develop new and/or improved clinical pathways to deliver PnD to patients for better therapeutic outcomes; identify the optimal strategy and PnD for the diseases with currently on going trials and opening new possibilities for PnD applications to other diseases, and

b) support the development of critical regulatory aspects of PnD to achieve successful clinical translation (WG4).

The Action will focus on diseases in which PnD applications are more advanced, such as bone and muscle regeneration and fibrotic, inflammatory disorders, as documented by the published results, that in turn will provide rationale for other therapeutic uses. 

Members:

Dirk Strunk (Austria)

Serhiy Forostyak (Czech Republic)

Racheli Ofir (Israel)

Ruta Navakauskiene (Lithuania)

Lenart Girandon (Slovenia)

 Marta Agudo-Barriuso (Spain)

Angel Esteban Gil (Spain)

Ekaterine Berishvili (Switzerland) 

Özlen Bektas (Turkey)
Paolo DeCoppi (United Kingdom)

Pedro Couto (United Kingdom)

COST_LOGO_HighRes.jpg
bandera_ue.jpg

Funded by the Horizon 2020 Framework Programme of the European Union

© 2019 SPRINT